Approval summary for bortezomib for injection in the treatment of multiple myeloma.
about
Specific small molecule inhibitors of Skp2-mediated p27 degradationNon-secretory multiple myeloma: from biology to clinical managementSustained proliferation in cancer: Mechanisms and novel therapeutic targetsProfound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodesBroad-spectrum agents for flaviviral infections: dengue, Zika and beyondThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Induction of Apoptosis in U937 Cells by Using a Combination of Bortezomib and Low-Intensity UltrasoundA pilot study of bortezomib in Korean patients with relapsed or refractory myelomaA phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group studyBortezomib: the evidence of its clinical impact in multiple myeloma.Regulatory role of proteasome in determination of platelet life spanNanodelivery in airway diseases: challenges and therapeutic applications.Synthesis and carbohydrate binding studies of fluorescent alpha-amidoboronic acids and the corresponding bisboronic acids.Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.Discovery and development of the anticancer agent salinosporamide A (NPI-0052).Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaCarbohydrate recognition by boronolectins, small molecules, and lectins.Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamidesSalinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosisThe ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsRegulating the 20S proteasome ubiquitin-independent degradation pathway.Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia.Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatmentSyrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death.Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLsTargeted therapies for prostate cancer.Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteinsBortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewHarnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
P2860
Q24596988-A042F1CA-0F22-45B3-996B-12D6573BAD6BQ28074785-5529B866-A65A-460C-A7BD-692D2CD59F68Q28396388-B21E6823-45AD-4D6E-B034-1CF6FCB28707Q28542496-68C90503-36F9-4056-8C98-DE558D73AF5DQ29994527-D35884C7-80FF-41D0-A016-4EA6DDA23434Q30248842-67CD0D62-B9C3-4176-8ACE-2781DC93008CQ30366081-ED953F00-AF0D-43BA-A060-C0506189D5BCQ33367833-300D8E0C-F8B6-47D7-83C5-CCA91C54CD3DQ33387006-0605468F-E7F5-400F-B7E9-8252C06288EAQ33398291-507947CE-2F41-42F2-8631-08A25AA8AD8EQ33400724-01A77BF3-9B8A-4E12-AB5D-07169497799DQ33405368-184FE113-F778-472E-AEC4-32082D68EE99Q33483926-342598F2-3814-4D92-B7BC-3CB0655BE070Q33529350-30E40C27-A04C-429B-A3D4-572B373909BCQ33584749-A60AF347-683D-40D2-827E-BA669B0D44FAQ33622960-275358C4-A63A-442F-9302-9D84703EF458Q33648344-F58C26FD-B829-4B7B-92EE-832A844ABB0FQ33691290-11E42E23-399B-40EF-B31E-74153AB3B689Q33836952-5253E5C6-6284-4808-8A3B-6413176ECD2DQ34142223-37AE81FA-BEFC-4178-BD50-AEEDD406DE53Q34154200-9C12D342-44A1-40B5-B11C-6CDB1D1288B5Q34195083-4D69A638-6F63-42AF-81EF-5AED20E90DFBQ34198852-B88375E2-A579-49E7-9281-03517E43253EQ34218976-473BB4F2-93CC-4CDD-85FA-B149A9C6E4E9Q34318192-8ADD8B3E-A32F-4361-AE55-D25F6223C50EQ35043552-29AE5E5E-C0DD-4369-936D-F432FA0712FBQ35083349-28D1554A-7DD1-47DE-9FDA-F4B727CCECA6Q35596882-11BFBC99-0212-46CB-99F5-F7FA1D34EE8CQ35663049-86D8F5BD-795F-495F-9196-8CD86EEDF7CCQ35933211-EB6F7E23-CD71-403E-A339-4CC57EFF1F17Q36028423-696B6103-3376-48AF-9AB5-D7C9D87CE661Q36150842-8297C7A2-97A9-4BBF-BBB4-1F3B68B2B0ADQ36204764-D0260774-A7D9-4CC2-8361-17708C1F87F3Q36216250-01856122-0CB5-4AB8-8F86-70F28CD25B4EQ36251308-0360C883-D7E5-46F0-A648-28BAA4B13319Q36301123-72F5F0FB-785A-4D37-8F23-A861D033FBAAQ36378038-8F72CB67-1382-488B-8B4B-904A8893B7ADQ36408216-5E69D385-9F56-4183-95A6-B2706421EDD4Q36413767-EFF5197F-7D9A-4E98-AC56-092FC819A4C1Q36544872-628A2492-DB92-4CCD-B618-A4140D256E91
P2860
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
@en
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
@nl
type
label
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
@en
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
@nl
prefLabel
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
@en
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
@nl
P2093
P1476
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
@en
P2093
Ann T Farrell
Anwar Goheer
Atiqur Rahman
Cheng Yi Liang
David E Morse
Grant Williams
Jogarao V Gobburu
John Leighton
Kimberly Benson
Lilliam A Rosario
P304
P356
10.1158/1078-0432.CCR-03-0781
P407
P433
P577
2004-06-01T00:00:00Z